Inactive Instrument

SHAN BIOM Stock NSE India S.E.

Equities

SHARONBIO

INE028B01029

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Dynamic Chart
Sharon Bio - Medicine Limited Announces Intimation Regarding Re-Commencement of Manufacturing Facility CI
Innova Captab Limited acquired Sharon Bio - Medicine Limited. CI
Sharon Bio - Medicine Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Sharon Bio - Medicine Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Sharon Bio - Medicine Limited Appoints Rakhi Makhloga as Company Secretary CI
Sharon Bio - Medicine Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Innova Captab Reportedly Places Bid for Sharon Bio-Medicine CI
Sharon Bio - Medicine Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2021 CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2021 CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Third Quarter Ended December 31, 2020 CI
Sharon Bio-Medicine Ltd. Reports Unaudited Earnings Results for the Quarter and Half Year Ended September 30, 2020 CI
More news
Managers TitleAgeSince
Chief Executive Officer - 18-05-23
Chairman 51 -
Compliance Officer - 23-01-22
Members of the board TitleAgeSince
Chairman 51 -
Chief Executive Officer - 18-05-23
More insiders
Sharon Bio-Medicine Limited is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and commercialization of pharmaceutical products. The Company operates in three segments, which include Active Pharma Ingredients (API's), Formulations and Toxicology. The Company offers various Active Pharmaceutical Ingredients, including Ketoconazole, Trimetazidine Di HCI, Glimepiride, Eperisone HCI, Memantine HCI, Telmisartan, Nifedipine, Aripiprazole and Atomoxetine HCI. The Company offers various intermediate products, including Cis Bromo Benzoate, N-Acetyl-4(4-Hydroxy Phenyl) Piperazine, Cis Tosylate and Tri Ethyl Benzyl Ammonium Chloride. The Company also offers various services, including preclinical toxicology on small animals, chemical process development and scale up, formulation development, analytical method development, drug master file (DMF) and dossier preparation, and commercial manufacturing of intermediates, actives and finished dosages.
Sector
-
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW